Metastatic Carcinoma PDX Models

Identifying robust preclinical models for metastatic carcinoma is essential for the development of cancer therapies. Patient Derived Xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity. The CrownBio metastatic carcinoma PDX collection consists of several models which will provide an accurate approach to predicting an agents efficacy prior to entering the clinic. More

Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL ID CANCER TYPE SUBTYPE models per page
MC0665 Metastatic Carcinoma SCC VIEW MODEL Details
MC1392 Metastatic Carcinoma NA VIEW MODEL Details
MC1454 Metastatic Carcinoma NA VIEW MODEL Details
MC2296 Metastatic Carcinoma NA VIEW MODEL Details
MC3050 Metastatic Carcinoma NA VIEW MODEL Details
MC3084 Metastatic Carcinoma NA VIEW MODEL Details
MC3128 Metastatic Carcinoma SCC VIEW MODEL Details
MC3160 Metastatic Carcinoma SCC VIEW MODEL Details
MC3359 Metastatic Carcinoma Adenocarcinoma VIEW MODEL Details
MC3405 Metastatic Carcinoma ADC VIEW MODEL Details